FDA Grants Accelerated Approval to Inovio’s Voceryq; Shares More Than Triple

The FDA approved Voceryq to reduce the frequency of surgery in adults with recurrent respiratory papillomatosis. Inovio shares more than tripled after hours to $2.17.